top of page

Press Releases

9
Jan
2024

Lirum Therapeutics Participates in the 13th Annual LifeSci Partners Corporate Access Event 

New York, NY – January 9, 2024 – Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that management is participating in the 13th Annual LifeSci Partners Corporate Access Event, which is taking place January 8-10, 2024 ....

31
Oct
2023

Lirum Therapeutics Presents Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy, Demonstrating Potent Preclinical Activity Against Pediatric Sarcomas 

New York, NY – October 31, 2023 – Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, today announced the presentation of positive data at the 2023 Connective Tissue Oncology Society meeting in Dublin, Ireland....

19
Oct
2023

Lirum Therapeutics to Present at the 2023 ThinkEquity Conference

New York, NY – October 19, 2023 – Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that Peter McDonald, the CEO of Lirum, will present at the 2023 ThinkEquity Conference on Thursday, October 19, 2023, at 2:00 PM ET. The conference will be held at the Mandarin Oriental Hotel in New York, NY.... 

5
June
2023

Lirum Therapeutics Presents Data on LX-101, A Novel Clinical-Stage Targeted Therapy, Demonstrating Potent Preclinical Activity Against a Range of Pediatric Cancers

New York, NY – June 5, 2023 – Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, today announced the presentation of positive data at the 7th Cancer World Congress in Palermo, Italy... 

8
Feb
2023

Lirum Therapeutics Announces Closing of $7 Million Private Placement of Common Stock

New York, NY – February 8, 2023 – Lirum Therapeutics, Inc. (the “Company” or “Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, today announced that it has closed a private placement, which resulted in gross proceeds to Lirum of over $7 million, before deducting offering expenses...

bottom of page